For the quarter ended March 2025, Zai Lab Limited Unsponsored ADR (ZLAB) reported revenue of $106.49 million, up 22.2% over the same period last year. EPS came in at -$0.45, compared to -$0.55 in the year-ago quarter.
The reported revenue represents a surprise of -9.06% over the Zacks Consensus Estimate of $117.09 million. With the consensus EPS estimate being -$0.50, the EPS surprise was +10.00%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Zai Lab Limited performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product Revenue- ZEJULA: $49.53 million versus the three-analyst average estimate of $48.32 million.
- Product Revenue- OPTUNE: $11.36 million versus the three-analyst average estimate of $8.35 million.
- Product Revenue- VYVGART: $18.11 million compared to the $31.75 million average estimate based on three analysts.
- Product Revenue- NUZYRA: $15.12 million versus the three-analyst average estimate of $14.39 million.
- Product Revenue- QINLOCK: $8.51 million versus the three-analyst average estimate of $8.21 million.
View all Key Company Metrics for Zai Lab Limited here>>>
Shares of Zai Lab Limited have returned +4.8% over the past month versus the Zacks S&P 500 composite's +11.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
